Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple mye...
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA Data signal potential of novel, off-the-shelf...
Johnson & Johnson CEO: 'We're in the Golden Era of Medical Innovation'
Johnson & Johnson Chairman and CEO Joaquin Duato believes that we are now in a “golden era” of innovation, particularly in the United States. Venture capital plays a vital early-stage role, but big...
Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today that Daniel Pinto, President, JPMorganChase, has been elected to its Board of Directors. “We are thrilled to have...
'No more tears': Author Gardiner Harris on J&J's controversies over the years
Gardiner Harris, ‘No More Tears' author and former New York Times correspondent, joins 'Squawk Box' to discuss the controversies and challenges facing Johnson & Johnson over the years.
These 2 Dividend Stocks Have Grown Dividends For 50 Consecutive Years. Can That Streak Continue?
It may be too soon to rotate back into the risk trade as market volatility calms.
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 16th to review second-quarter results. J...
Johnson & Johnson (JNJ) Presents at the Bernstein's 41st Annual Strategic Decisions Conference (Transcript)
Johnson & Johnson (NYSE:JNJ ) Bernstein's 41st Annual Strategic Decisions Conference Call May 28, 2025 9:00 AM ET Company Participants Joaquin Duato - Chairman and Chief Executive Officer Joseph Wo...
Johnson & Johnson (JNJ) Declines More Than Market: Some Information for Investors
In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $152.51, denoting a -0.44% change from the preceding trading day.
JNJ Down 6% in 3 Months: How to Play the Stock Amid Various Challenges
J&J's JNJ stock has declined 6.4% in the past three months. J&J faces several challenges, including slowing sales in the MedTech segment, loss of exclusivity of its blockbuster drug, Stelara, and u...
Johnson & Johnson to Participate in the Bernstein's 41st Annual Strategic Decisions Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Bernstein's 41st Annual Strategic Decisions Conference on Wednesday, May 28th, 2025. Management will particip...
Johnson & Johnson (JNJ) RBC Capital Markets Global Healthcare Conference
Johnson & Johnson (NYSE:JNJ ) RBC Capital Markets Global Healthcare Conference May 20, 2025 1:35 PM ET Corporate Participants Joe Wolk - EVP, Chief Financial Officer Conference Call Participants Sh...
Here's Why Johnson & Johnson (JNJ) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Johnson & Johnson: For Those Who Want Some Immunity Against Tariff Changes
The U.S. and China have agreed to reduce tariffs temporarily for 90 days. I expect continued market volatility in the negotiation process. Johnson & Johnson could offer some immunity due to the spe...
J&J Oral Psoriasis Drug Meets Primary Goal in Late-Stage Study
Data from a late-stage study shows that treatment with JNJ's icotrokinra helps achieve significant skin clearance in hard-to-treat scalp and genital psoriasis.
Fortress Dividends: 2 Of The Best All-Weather Income Stocks Built To Last
Market turmoil often triggers a rush to 'safe' assets, but I believe these moments are best for buying cyclical stocks with strong upside potential. Rather than chasing what's popular, I focus on a...
Related Companies